Telavancin

Lipoglycopeptide Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Telavancin is a drug in the Lipoglycopeptide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2009. Recorded indications include Bacterial pneumonia, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Infection and Complicated Skin and Skin Structure Staphylococcus Aureus Infection.

• Drug class: Lipoglycopeptide Antibacterial.
• Indications: Bacterial pneumonia, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Infection, Complicated Skin and Skin Structure Staphylococcus Aureus Infection and Complicated Skin and Skin Structure Streptococcus Agalactiae Infection and others.
• ATC code: J01XA03 (Glycopeptide antibacterials).
• Molecular formula: C80H106Cl2N11O27P; molecular weight 1755.65 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Bacterial pneumonia
• Complicated Skin and Skin Structure Enterococcus Faecalis Infection
• Complicated Skin and Skin Structure Infection
• Complicated Skin and Skin Structure Staphylococcus Aureus Infection
• Complicated Skin and Skin Structure Streptococcus Agalactiae Infection
• Complicated Skin and Skin Structure Streptococcus Pyogenes Infection
• Pneumonia due to Staphylococcus aureus

Contraindications (11)

• Chronic heart failure
• Congenital long QT syndrome
• Decompensated cardiac failure
• Diabetes mellitus
• Hypertensive disorder
• Impaired renal function disorder
• Kidney disease
• Pregnancy, function
• Prolonged QT interval
• Pseudomembranous enterocolitis
• Torsades de pointes

Mechanism & targets

• Established pharmacologic class: Lipoglycopeptide Antibacterial

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2009-09-11	FDA	—	THERAVANCE BIOPHARMA

ATC classification

ATC code	Therapeutic hierarchy
J01XA03	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Glycopeptide antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Tubulointerstitial nephritis	98.1
Hypertensive heart disease	94.2
Acute kidney injury	80.0
Klebsiella infection	76.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Telavancin is on its molecule page.

• Molecular formula: C₈₀H₁₀₆Cl₂N₁₁O₂₇P
• Molecular weight: 1755.65 g/mol
• CAS number: 372151-71-8
• InChIKey: ONUMZHGUFYIKPM-MXNFEBESSA-N
• PubChem CID: 3081362

CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=CC=C(C=C2Cl)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC=C(O)C(=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Telavancin used for?

DrugCentral lists the following indications for Telavancin: Bacterial pneumonia, Complicated Skin and Skin Structure Enterococcus Faecalis Infection, Complicated Skin and Skin Structure Infection, Complicated Skin and Skin Structure Staphylococcus Aureus Infection, Complicated Skin and Skin Structure Streptococcus Agalactiae Infection, Complicated Skin and Skin Structure Streptococcus Pyogenes Infection and Pneumonia due to Staphylococcus aureus.

When was Telavancin first approved?

Telavancin was first approved by the FDA in 2009.

What drug class does Telavancin belong to?

Telavancin is in the Lipoglycopeptide Antibacterial class.

What is the chemical formula of Telavancin?

Telavancin has the molecular formula C80H106Cl2N11O27P and a molecular weight of 1755.65 g/mol.

Sources

• DrugCentral drug card 4116 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3301680 — compound record and bioactivity
• PubChem CID 3081362 — chemical identifiers
• DrugBank DB06402 — drug record
• FDA UNII XK134822Z0 — substance identity
• DailyMed: FDA labels for Telavancin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.